Autres langues Foresee Pharmaceuticals Co., Ltd.

Actions

6576

TW0006576002

Recherche biotechnologique et médicale

Cours en clôture Taipei Exchange 30/09/2026			Varia. 5j.	Varia. 1 janv.
79,50 ^TWD	-0,25%		-1,73%	-1,36%

14/08	Foresee Pharmaceuticals Co., Ltd. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
09/07	Foresee Pharmaceuticals Co., Ltd. annonce la nomination de Brian J. Groch au poste de Directeur Commercial, à compter du 1er juillet 2026	CI

Autres langues

14/08	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
09/07	Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026
08/06	Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial
27/05	Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty
14/05	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/03	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
06/03	Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union
04/02	Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty
24/12	Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate
13/11	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
29/08/25	Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer
12/08/25	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
31/07/25	Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive TWD 400 million in funding
17/06/25	Foresee Completes Phase 3 CASPPIAN Trial Enrollment For Central Precocious Puberty
17/06/25	Foresee Pharmaceuticals Announces Complete Enrollment of its Phase 3 Casppian Trial for Patients with Central Precocious Puberty
30/05/25	Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A Maa for the 3-Month Version of Camev by Accord Healthcare
15/05/25	Foresee Pharmaceuticals Co., Ltd. Announces the First Patient Dosed in Its Phase 2 Trial of Mirivadelgat (FP-045) in Patients with PH-ILD
14/05/25	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
25/04/25	Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A NDS for the 3-Month Version of Camcevi by Accord Healthcare
28/03/25	Foresee Pharmaceuticals Co., Ltd. Announces the Maa for the 3-Month Version of CAMCEVI Is Accepted for Scientific Assessment by the EMA for the Treatment of Advanced Prostate Cancer
17/03/25	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
12/03/25	Foresee Pharmaceuticals Co., Ltd. cancelled the transaction announced on March 12, 2025
12/03/25	Foresee Pharmaceuticals Co., Ltd. announced a financing transaction
27/02/25	Foresee Pharmaceuticals Shifts Focus from Fanconi Anemia to PH-ILD in Phase 2 Trials with Mirivadelgat (FP-045)
18/02/25	Foresee Pharmaceuticals Co., Ltd. Announces the MAA of Leuprolide Injectable Emulsion Was Accepted for A Substantive Review by China NMPA for The Treatment of Advanced Prostate Cancer